Abstract: The present invention discloses a method of treating neurodegenerative disorder comprising administering an effective amount of an alkaloid which is a bisbenzylisoquinline alkaloid isolated from the traditional Chinese medicinal herb Nelumbo nucifera. The pharmaceutical composition thereof for treating Huntington's disease is also disclosed.

Abstract: The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:

Abstract: A variety of products are obtained from modified guar protein extracts, for example, cosmetic or pharmacological or plant protective compositions or domestic care agents containing such products; these are particularly suitable for treating and/or modifying and/or coating the skin, hair, hard and textile surfaces and, notably, plant leaf surfaces.

Abstract: The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes.

Abstract: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.

Abstract: A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier. The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject.

Abstract: There are provided inter alia compounds of formula (I) useful as cyclophilin inhibitors.

Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a substituted quinazolinone compound and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.

Abstract: A composition and method for the treatment of the side-effects associated with the administration of cancer chemotherapeutic agents involves the oral ingestion of a slow release capsule containing adenine. In some embodiments, the slow release capsule also contains orotate. The systemic administration of a proton pump inhibitor decreases systemic absorption of orotate, and the systemic administration of allopurinol decreases the formation of 2,8-dihydroxy adenine from adenine. In an alternative embodiment, cationic liposomes contain purine/pyrimidine precursors. The cationic liposomes bind to the cells lining the mucosa of the intestinal tract and then the contents of the cationic liposome are then taken up in the interior of the cells to prevent the metabolism of the cancer treatment drug 5-FU into a toxic species. A method for prevention of oral stomatitis and a method for treatment of dysplastic tissue are also disclosed.

Abstract: A method of treating cancer using a dihydropyrimidine derivative includes administering to a patient a therapeutically effective amount of a dihydropyrimidine derivative having the following formula: wherein: R2 is S or O and R, R1, R3, and R4 each independently represent hydrogen, optionally substituted straight-chain or branched C1 to C7 alkyl, halogen, optionally substituted haloalkyl, alkoxy or haloalkoxy in which the alkyl is straight-chain or branched C1-C4 alkyl and the halo derivatives are mono, di, tri or poly halosubstituted, the optional substituents including halogen, amino, substituted amino, C1-C4 alkyl, halo (C1-C4) alkyl, alkoxy or haloalkoxy having C1-C4 alkyl group, or R, R1, R3, and R4 each independently represent aryl, substituted aryl, heteroaryl, or substituted heteroaryl, the substituents including halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, alkylamino, aryl, heteroaryl, aryloxy, haloaryloxy, arylthio, or arylamino; or a pharmaceutically acceptable salt thereof.

Abstract: HslVU is the proteasome-related system composed of HslV peptidase and HslU chaperone. It is involved in intracellular proteolysis. The presence of HslVU homologs in pathogenic microbes and its absence in human makes it an antimicrobial drug target. The functional HslVU complex forms when HslV dodecamer is flanked at both ends by HslU hexamers. In the HslVU complex, intercalation of C-termini residues of HslU subunits into the clefts between adjacent HslV subunits results in allosteric activation of HslV. We identified small molecules capable of activating HslV peptidase in the absence of its natural activator HslU. Quinazoline and chromone derivatives were suggested by ligand docking to bind at the HslU C-termini intercalation pockets in the HslV. This was confirmed by HslV activation assays with these compounds that gave ED50 in sub-micromolar range. The results showed that small, extracellular non-peptidic molecules can activate the HslV peptidase which in turn would initiate intracellular proteolysis.

Abstract: The invention features methods and compositions feature lapatinib and/or rapamycin for treating or preventing a cardiac condition induced by anthracycline treatment.

Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.

Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.

Abstract: An adhesive patch is provided in which piroxicam is formulated as a non-steroidal anti-inflammatory analgesic. In particular, provided is a piroxicam-containing transdermally absorbable adhesive patch in which an absorption promoter to piroxicam is formulated to achieve high anti-inflammatory and analgesic effects without inhibiting releasing of these drugs. The piroxicam-containing transdermally absorbable adhesive patch contains piroxicam as a medicinal component and oxybuprocaine or a pharmaceutically acceptable salt thereof as an absorption promoter. In the piroxicam-containing transdermally absorbable adhesive patch, the content of piroxicam is from 0.1% to 5% by weight to the total weight of a drug-containing plaster and the content of oxybuprocaine or the pharmaceutically acceptable salt thereof is from 1% to 30% by weight to the total weight of the drug-containing plaster.

Abstract: Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: ?12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. ?12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. ?12-prostaglandin J3 was shown to be highly effective in eradicating the leukemia stem cells (LSC) in two murine models of leukemia, thus increasing the survival of the mice. DP agonists were shown to induce apoptosis of human primary Acute Myelogenous Leukemia cells and may be used in compositions, kits and methods for treating leukemia in a subject. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.

Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

Abstract: The present invention discloses pharmaceutical/nutritional compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical/nutritional compositions include at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery.

Abstract: The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed.

Abstract: A polyphenol composition derived from Camellia sinensis and contains flavonol aglycones and flavonol glycosides, in a weight ratio [(B)/(A)] of the following total contents (B) to (A) is from 0.01 to 18, wherein (A) total content of the flavonol aglycones contained in solids of the polyphenol composition after hydrolysis as measured by high-performance liquid chromatography, and (B) total content of the polyphenols contained in solids of the polyphenol composition as measured by the ferrous tartrate method.

Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.

Abstract: Isolated MUC17, Muc3 or MUC3 derived polypeptides and polynucleotides encoding the same are described. The MUC17, Muc3 or MUC3 derived polypeptides, polynucleotides, and pharmaceutical compositions can be used to treat gastrointestinal tract diseases and disorders including, inflammatory bowel disease and its associated colitides, for example, Crohn's Disease.

Abstract: A joint-lubricating composition for treating degenerative joint disorders is provided, having microalgal polysaccharides in an aqueous solution, wherein the polysaccharides are stable and non-immunogenic. Further provided is a method for treating a joint disorder by injecting into the joint a viscous aqueous solution of a polysaccharide, wherein the disorder is, for example, arthritis, and the polysaccharide originates, for example, from a red alga.

Abstract: A method for treating cerebral edema or complications thereof is disclosed. The method comprises administering a herbal medicinal composition to a subject in need, wherein the herbal medicinal composition comprises 1.3-5.3 parts by weight of Chaihu, 2.2-8.8 parts by weight of Hunagqing, 1.8-7.0 parts by weight of Panxia, 1.8-7.0 parts by weight of Chishaoyao, 0.5-1.8 parts by weight of Dahuang, 1.3-5.3 parts by weight of Zhishi, 2.2-8.8 parts by weight of Hungtsao, 4.4-17.5 parts by weight of Fuling, 1.8-7.0 parts by weight of Chuling, 2.2-8.8 parts by weight of Zerxie, 1.8-7.0 parts by weight of Changchu, 1.3-5.3 parts by weight of Mahuang, 1.8-7.0 parts by weight of Dansheng, 2.2-8.8 parts by weight of Chuanxiong, 2.2-8.8 parts by weight of Wuchuyu, 2.2-8.8 parts by weight of Tienma, 1.3-5.3 parts by weight of Ginseng, and 1.3-5.3 parts by weight of Chuanchi.

Abstract: The present invention relates to a garlic formulation enriched with sulphur containing amino acids and a process for enriching sulphur containing amino acids in garlic. The sulphur containing amino acids includes S-allylcysteine, S-methylcysteine, and S-allylmercaptocysteine. The percentage of enriched garlic concentrate after processing is in the range of 7.5-9.5%. The garlic formulation is useful in the treatment of Diabetes Mellitus (DM) and prevention of tissue and organ damage that occurs frequently in diabetic patients.

Abstract: A composition based on a poly-organosiloxane which is suitable for its use as a bolus in radiotherapy treatments. Other possible uses of this composition are the production of an immobilizing mask for radio surgery or cranial stereotaxy treatments and the production of an intraoral depressor.

Abstract: Provided herein are compounds useful for selectively labeling an apoptotic cell, and methods and assays using such compounds for the detection of an apoptotic cell in vivo or in a biological sample obtained from a subject.

Abstract: A silica particle for medical imaging includes a bridged silane fluorescent dye incorporated throughout the particle matrix. Copolymerization of a bridged silane fluorescent dye (e.g., (R?O)3Si—R—Si(OR?)3, where R is a fluorescent organic bridging group, and where R? is a methyl or ethyl group) and a tetralkoxysilane (e.g., Si(OR?)4, where R? is a methyl or ethyl group) generates particles of a predetermined size and shape. This leaves the surface of each particle available for further modification to facilitate dispersion of the particle into different media. Hence, a surface modifier may be subsequently bonded onto the particle surface. In some embodiments, poly(ethylene glycol) is selected as the surface modifier to increase dispersion of the silica particle in an aqueous media. In some embodiments, the particle is porous allowing for an additional functionality (e.g., a secondary imaging material, such as magnetic nanoparticles, and/or a pharmaceutical drug) to be loaded within the pores.

Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.

Abstract: The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of an alkylating or alkylating-like agent, an antimetabolite agent, a topoisomerase I inhibitor, a topoisomerase II inhibitor, an inhibitor of a growth factor or of a growth factor receptor, an antimitotic agent, a proteasome inhibitor, an inhibitor of an anti-apoptotic protein and an antibody directed against a cell surface protein, wherein the active ingredients are present in each case in lice form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.

Abstract: A method for reducing the frequency of urination is disclosed. The method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents and one or more ?-blockers. In one embodiment, the one or more analgesic agents are formulated for extended-release.

Abstract: Described herein are compositions comprising a quinone and one or more antibacterial agents, and methods of preparing and using the same.

Abstract: The present invention provides methods for treating acute kidney injury through introduction of one or more drag reducing polymers, oligomers, and/or monomers, as well as compositions that include therapeutic amounts of one or more of these drag reducing polymers, oligomers, and/or monomers. These compositions may also include additional components that enhance at least one of the stability, effectiveness, or administerability of the polymers, oligomers, and/or monomers—such as buffers, anti-oxidants, and enzyme inhibitors.

Abstract: The present invention provides combinations, for treatment of subjects suffering from or at high risk of developing diseases and disorders involving expression of peroxisome proliferator-activated receptors (PPAR). The combinations include abscisic acid and one other bioactive agent, which together provide synergistic effects toward treatment or blocking of development of the disease or disorder. In exemplary embodiments, a combination of abscisic acid and a thiazolidinedione (TZD) is provided for increased insulin sensitivity and improved (i.e., reduced) obesity-induced inflammation.

Abstract: Disclosed is an adjuvant for improving the bioavailability of bioactive compositions. The adjuvant is prepared from a byproduct of mint flavor production. In vitro and in vivo testing confirms effectiveness. The adjuvant contains a mixture of compounds which is effective to improve the oral bioavailability of a bioactive composition normally having limited absorptivity, and it comprises a mixture of nonpolar compounds and compounds with some polar characteristics. In preferred form the nonpolar compounds comprise compounds selected from a group that includes terpene hydrocarbons and terpene derivatives and the compounds with some polar characteristics comprise compounds selected from a group that includes aldehydes, alcohols and ketones. The preferred compositions will have a ratio of nonpolar compounds and compounds with some polar characteristics is within the range of from 5:1 to 20:1. The adjuvants can enhance delivery of CoQ10 and other bioactive compositions, such as carotenoids (e.g.

Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.

Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.

Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.

Abstract: This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles that contain either samarium-yttrium, samarium, or lutetium as medical isotopes for radiotherapy and/or radioimaging.

Abstract: This invention includes methods for cleaning and sterilizing tissue harvested for implant with shock waves by submerging the harvested tissue in a volume of fluid in a holding vessel including a shock wave applicator with a focal volume in the volume of fluid, and applying a pressure shock wave pulses to the harvested tissue from the shock wave applicator in sufficient amounts to eliminate biological contaminants in the harvested tissue.

Abstract: System for sterilization of objects (B) by electron bombardment comprising a chamber (2) provided with an inlet (4) and an outlet (6) through which objects (B) are input and output, said system between the inlet (4) and the outlet (6) comprising a treatment zone (II), a routing zone (I) upstream from the treatment zone (II) and an evacuation zone (III) downstream from the treatment zone (II), and means of conveying objects (B) from the inlet (4) to the outlet (6), the treatment zone (II) comprising at least one electron accelerator and a conveyor (9), the routing zone (I) and the evacuation zone (III) each including at least one radiation shielding wall (16) protecting against ionizing radiation and means allowing objects (B) to pass over the radiation shielding wall (16) passing over the top of said radiation shielding wall (16).

Abstract: The invention relates to a method and device for influencing the smell coming from shaft openings of underground sewers, in which water droplets are sprayed into the air in shafts (1) of underground sewers which are open in the direction of the ambient air. Said spraying device comprises a pressure vessel (3) containing water and a nozzle (4) having one or more fine openings through which water can escape from the pressure vessel (3), the pressure vessel (3) being subject to a hydrostatic pressure which is by at least 2 bars greater than the ambient pressure, and the diameter of one or more nozzle openings being less than 130 ?m.

Abstract: In embodiments, a control system for a UV air treatment system, especially one used for cleaning a fume stream such as in a kitchen exhaust system, detects a need for cleaning maintenance on the UV light source based on changes in light intensity. The system further detects the light intensity each time the UV light source is cleaned to determine if the drop in intensity after cleaning indicates that the UV light source should be replaced. The cleaning and replacement requirements are indicated automatically by a user interface.

Abstract: A process and apparatus for cleaning and disinfection of textiles and the air from viruses, bacteria and spores, and also for purifying from dust, pollen, odors, etc. in which the employment of water and various other cleaning agents and disinfectants as well is not required includes a lock or chamberin which living beings are able to stay, and piece-goods and textiles, etc. are able to be treated as well. Therein, airborne aerosols (droplets, particles, dust) as well as aerosols and microbes, respectively, adhering to the clothing or body and to the product, respectively, are to be treated. The basic principle shall also be applicable to rooms (e.g. waiting rooms) or stables and under cleanroom conditions as well. Various aspects of the invention include plasma generation, producing an ion current from the plasma, ozone generation and activation, sterilization, oxidation and decomposition of gaseous components, and separation of microbes and aerosols and decomposition thereof.

Abstract: A suture assembly comprising: a first suture having a generally O-shaped configuration comprising a first arm, a second arm, a first bridge connecting the first arm to the second arm, and a second bridge connecting the first arm to the second arm, the first bridge opposing the second bridge so that the first suture comprises a closed loop; a second suture comprising a first arm, a second arm and a bridge connecting the first arm to the second arm; the first arm of the second suture being wrapped around the first arm of the first suture in a first direction, and the second arm of the second suture being wrapped around the second arm of the first suture in a second, opposite direction; the suture assembly being capable of assuming (i) a longitudinally-extended, radially-contracted first configuration, and (ii) a longitudinally-contracted, radially-expanded second configuration.

Abstract: A method for modifying a non-woven fabric of chitosan fiber. The method includes: adding succinic anhydride to an industrial alcohol, ethanol, or acetone; controlling the mass ratio of succinic anhydride to the non-woven fabric at between 0.8 and 3.5; and stirring the resulting mixture until the succinic anhydride has dissolved to yield a succinic anhydride mixed solution; placing the succinic anhydride mixed solution in a constant temperature shaking bath; heating the succinic anhydride mixed solution; adding an HCl solution to the succinic anhydride mixed solution, and stirring evenly to yield a HCl mixed solution; immersing the non-woven fabric in the HCl mixed solution; dehydrating; immersing the non-woven fabric in ethanol or acetone; immersing the non-woven fabric in anhydrous ethanol or pure acetone; dehydrating; and air drying the non-woven fabric.

Abstract: Disclosed is a self-adhesive matrix system comprising a styrene-ethylene/butylene-styrene (SEBS) copolymer in an oil/ethyl acetate mixture, a hydrogenated resin and a pharmaceutical or cosmetic active ingredient.

Abstract: The invention provides a polymeric medical sealant. The medical sealant is useful for application to the tonsils and adenoids, wherein the sealant performs at least one of the following functions, a) inhibit the colonization of bacteria, b) inhibit the binding of bacteria to tissue, c) reduction of tissue morbidity, d) hemostasis, e) coating and protection of tissue during healing. f) promotion of healing, and g) reduction of pain.